The company said it experienced “productivity issues” at its gene therapy manufacturing site and faced similar issues at its drug product and drug substance manufacturing facilities.
https://www.pharmalive.com/wp-content/uploads/2023/04/Catalent.jpg500724Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2023-04-14 07:50:062023-04-14 08:16:17Contract drug manufacturer Catalent warns of hit from costs, low production
